Login Register Cart 0
Generic placeholder image

Recent Advances in Anti-Infective Drug Discovery

Editor-in-Chief

ISSN (Print): 2772-4344
ISSN (Online): 2772-4352

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Research Article

Outpatient Intravenous Remdesivir to Prevent Progression to Severe COVID-19: An Observational Study from a Greek Hospital

Author(s): Nikolaos Kintrilis* and Iosif Galinos

Volume 19, Issue 2, 2024

Published on: 08 May, 2023

Page: [173 - 178] Pages: 6

DOI: 10.2174/2772434418666230331083714

Price: $65

Abstract

Background: Remdesivir, a viral RNA polymerase inhibitor, has been a powerful weapon in the battle against the SARS-CoV-2 pandemic. Originally approved for use in hospitalized patients, remdesivir improves clinical outcomes in patients with moderate to severe coronavirus disease 2019 (COVID-19). After proving efficacious in hospitalized patients, its use was approved in early disease for symptomatic, non-hospitalized patients that present risk factors for progression to severe disease.

Objective: To evaluate whether administration of the antiviral medication remdesivir at an outpatient basis has an effect on hospital admissions of patients presenting with SARSCoV- 2 infection.

Methods: We conducted an observational clinical trial involving 107 non-hospitalized COVID-19 patients who attended the emergency department of a third-level greek hospital seeking care for symptoms appearing within the previous 5 days and who had at least one risk factor for progression to severe disease. After arterial blood gas evaluation, eligible patients received intravenous remdesivir at a dose of 200 mg on day 1 and 100 mg on days 2 and 3. The efficacy endpoint was set as COVID-19-related hospitalization or death in the next 14 days.

Results: A total of 107 patients (57.0% men) participated in the study, 51 (47.7%) of them fully vaccinated. Most prevalent were age ≥ 60 years old, cardiovascular/cerebrovascular disease, immunosuppression or malignancy, obesity, diabetes mellitus, and chronic lung disease. All patients enrolled completed the 3-day course, with a total of 3 out of 107 patients (2.8%) eventually having a COVID-19-related hospitalization by day 14, while no deaths were reported by day 14.

Conclusion: Among non-hospitalized patients with at least one risk factor for progression to severe COVID-19, a 3-day course of intravenous remdesivir yielded favourable results.

« Previous Next »
[1]
World Health Organization Available from: https://covid19.who.int/table
[2]
Gao Y, Ding M, Dong X, et al. Risk factors for severe and critically ill COVID‐19 patients. : A review Allergy 2021; 76(2): 428-55.
[http://dx.doi.org/10.1111/all.14657] [PMID: 33185910]
[3]
Booth A, Reed AB, Ponzo S, et al. Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis. PLoS One 2021; 16(3): e0247461.
[http://dx.doi.org/10.1371/journal.pone.0247461] [PMID: 33661992]
[4]
Molani S, Hernandez PV, Roper RT, et al. Risk factors for severe COVID-19 differ by age for hospitalized adults. Sci Rep 2022; 12(1): 6568.
[http://dx.doi.org/10.1038/s41598-022-10344-3] [PMID: 35484176]
[5]
Rashad A, Nafady A, Hassan MH, et al. Therapeutic efficacy of macrolides in management of patients with mild COVID-19. Sci Rep 2021; 11(1): 16361.
[http://dx.doi.org/10.1038/s41598-021-95900-z] [PMID: 34381155]
[6]
Poddighe D, Aljofan M. Clinical evidences on the antiviral properties of macrolide antibiotics in the COVID-19 era and beyond. Antivir Chem Chemother 2020; 28.
[http://dx.doi.org/10.1177/2040206620961712] [PMID: 32972196]
[7]
Kushner P, McCarberg BH, Grange L, et al. The use of non-steroidal anti-inflammatory drugs (NSAIDs) in COVID-19. NPJ Prim Care Respir Med 2022; 32(1): 35.
[http://dx.doi.org/10.1038/s41533-022-00300-z] [PMID: 36127354]
[8]
Cruciani M, Pati I, Masiello F, Pupella S, De Angelis V. Corticosteroids use for COVID-19: An overview of systematic reviews. Infez Med 2022; 30(4): 469-79.
[http://dx.doi.org/10.53854/liim-3004-1] [PMID: 36482954]
[9]
Chaharom EF, Pourafkari L, Ebrahimi Chaharom AA, Nader ND. Effects of corticosteroids on COVID-19 patients: A systematic review and meta-analysis on clinical outcomes. Pulm Pharmacol Ther 2022; 72(102107): 102107.
[http://dx.doi.org/10.1016/j.pupt.2021.102107] [PMID: 34933068]
[10]
Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 2017; 9(396): eaal3653.
[http://dx.doi.org/10.1126/scitranslmed.aal3653] [PMID: 28659436]
[11]
Gupte V, Hegde R, Sawant S, et al. Safety and clinical outcomes of remdesivir in hospitalised COVID-19 patients: A retrospective analysis of active surveillance database. BMC Infect Dis 2022; 22(1): 1.
[http://dx.doi.org/10.1186/s12879-021-07004-8] [PMID: 34983406]
[12]
Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30(3): 269-71.
[http://dx.doi.org/10.1038/s41422-020-0282-0] [PMID: 32020029]
[13]
Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of COVID-19 - final report. N Engl J Med 2020; 383(19): 1813-26.
[http://dx.doi.org/10.1056/NEJMoa2007764] [PMID: 32445440]
[14]
Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe COVID-19 in outpatients. N Engl J Med 2022; 386(4): 305-15.
[http://dx.doi.org/10.1056/NEJMoa2116846] [PMID: 34937145]
[15]
Siettos C, Anastassopoulou C, Tsiamis C, Vrioni G, Tsakris A. A bulletin from Greece: A health system under the pressure of the second COVID-19 wave. Pathog Glob Health 2021; 115(3): 133-4.
[http://dx.doi.org/10.1080/20477724.2021.1881372] [PMID: 33533705]
[16]
Giannopoulou I, Tsobanoglou GO. COVID-19 pandemic: Challenges and opportunities for the Greek health care system. Ir J Psychol Med 2020; 37(3): 226-30.
[http://dx.doi.org/10.1017/ipm.2020.35] [PMID: 32406360]
[17]
Iliopoulos DC. COVID-19: A Greek perspective. J Card Surg 2021; 36(5): 1637-40.
[http://dx.doi.org/10.1111/jocs.15027] [PMID: 32985717]
[18]
Chen RE, Winkler ES, Case JB, et al. In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. Nature 2021; 596(7870): 103-8.
[http://dx.doi.org/10.1038/s41586-021-03720-y] [PMID: 34153975]
[19]
Izcovich A, Siemieniuk RA, Bartoszko JJ, et al. Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: Systematic review and meta-analysis of randomised trials. BMJ Open 2022; 12(3): e048502.
[http://dx.doi.org/10.1136/bmjopen-2020-048502] [PMID: 35236729]
[20]
Ali K, Azher T, Baqi M, et al. Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: A randomized controlled trial. CMAJ 2022; 194(7): E242-51.
[http://dx.doi.org/10.1503/cmaj.211698] [PMID: 35045989]
[21]
Angamo MT, Mohammed MA, Peterson GM. Efficacy and safety of remdesivir in hospitalised COVID-19 patients: A systematic review and meta-analysis. Infection 2022; 50(1): 27-41.
[http://dx.doi.org/10.1007/s15010-021-01671-0] [PMID: 34331674]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy